Labcorp (NYSE:LH) Price Target Raised to $396.00

Labcorp (NYSE:LH) had its target price lifted by investment analysts at Robert W. Baird from $361.00 to $396.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird‘s price target would indicate a potential upside of 9.94% from the company’s previous close.

Other research analysts have also issued reports about the company. Leerink Partners set a $410.00 target price on Labcorp in a report on Wednesday. Mizuho set a $355.00 price target on Labcorp in a report on Monday, August 10th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $306.00 price objective on shares of Labcorp in a research report on Friday, July 31st. Truist Financial upped their price objective on shares of Labcorp from $350.00 to $365.00 and gave the company a “buy” rating in a report on Monday, September 21st. Finally, Piper Sandler raised their target price on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $351.58.

Labcorp Stock Up 8.8%

Shares of LH stock opened at $360.21 on Thursday. The firm’s fifty day moving average price is $321.91 and its two-hundred day moving average price is $286.47. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. Labcorp has a 1 year low of $244.52 and a 1 year high of $371.00. The firm has a market capitalization of $29.21 billion, a P/E ratio of 29.79, a PEG ratio of 1.88 and a beta of 0.87.

Labcorp (NYSE:LH) last released its quarterly earnings data on Wednesday, October 28th. The medical research company reported $4.78 EPS for the quarter, beating the consensus estimate of $4.64 by $0.14. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm posted $4.18 EPS. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. On average, equities analysts predict that Labcorp will post 18.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Adam H. Schechter sold 4,669 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total value of $1,495,807.53. Following the sale, the chief executive officer directly owned 102,565 shares in the company, valued at approximately $32,858,749.05. This trade represents a 4.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy B. Summy sold 924 shares of the company’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total transaction of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares of the company’s stock, valued at $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,593 shares of company stock worth $2,733,295 in the last 90 days. Company insiders own 0.84% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Diamond Hill Capital Management LLC Investment Advisor bought a new position in Labcorp during the 2nd quarter valued at approximately $168,222,000. Bank of New York Mellon Corp bought a new position in shares of Labcorp during the second quarter valued at $142,125,000. Madison Asset Management LLC bought a new position in shares of Labcorp in the second quarter worth approximately $133,460,000. Bessemer Group Inc. boosted its stake in Labcorp by 47.3% during the 1st quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock valued at $154,493,000 after purchasing an additional 185,847 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Labcorp by 19.4% in the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock worth $218,901,000 after buying an additional 133,549 shares in the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q3 results exceeded expectations: Labcorp reported adjusted earnings of $4.78 per share, above the $4.64 consensus estimate, while revenue rose 6.9% year over year to $3.81 billion, topping expectations of approximately $3.76 billion. Earnings increased from $4.18 per share in the prior-year quarter. Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
• Positive Sentiment: Full-year guidance was raised: Management increased its 2026 enterprise revenue-growth outlook to 5.9%-6.7% and adjusted EPS guidance to $18.30-$18.70, signaling confidence in operating momentum and supporting the stock’s advance. Labcorp Boosts FY26 Outlook
• Positive Sentiment: Growth was broad-based: Diagnostics Laboratories revenue climbed 6.5% to $2.95 billion, while Biopharma Laboratory Services revenue rose 8.5% to $866.7 million. Expanding margins also contributed to the stronger outlook. LH Stock Rises on Q3 Earnings and Revenue Beat
• Positive Sentiment: Portfolio expansion may support future growth: Labcorp announced or closed four transactions, including the acquisition of MLM Medical Labs and agreements involving BioReference Health, Myriad Genetics and Millennium Health. The FDA also approved Labcorp’s PGDx elio tissue complete CDx companion diagnostic for advanced melanoma. Labcorp Q3 2026 Earnings: Earnings Beat, Guidance Raised, Four Deals Pending
• Neutral Sentiment: Labcorp is also partnering with Waters to expand access to FDA-approved HPV screening tests by late 2026, which could increase testing adoption but is a longer-term catalyst. Waters and Labcorp Expand Access to HPV Screening Tests
• Negative Sentiment: Recent disclosures show insider selling, with no reported insider purchases over the past six months. While not necessarily tied to business fundamentals, the activity may temper investor enthusiasm after the strong rally.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.